Lead researcher Jin Hokyung said, "Our study identified the nasopharyngeal lymphatic plexus as a hub for CSF outflow. CSF ...

Researchers from Taiwan have recently published the results of a study on preradiotherapy imaging for nasopharyngeal carcinoma (NPC). To the authors' knowledge, this is the first study of this ...

therapy in combination with radiotherapy is an effective treatment for late-stage nasopharyngeal carcinoma (NPC). The authors conclude that radiotherapy combined with intratumoral administration ...

Considering taking supplements to treat nasopharyngeal cancer? Below is a list of common natural remedies used to treat or reduce the symptoms of nasopharyngeal cancer. Follow the links to read ...

Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the upper part of the throat. The company has launched Toripalimab, a new ...

in India under the brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of head and neck cancer. Loqtorzi, a novel anti-PD-1 ...

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare ...

“The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal carcinoma (NPC) in India. NPC is a rare form of head and neck cancer. However, the prognosis of ...

Reddy’s, said: “The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal carcinoma (NPC) in India. NPC is a rare form of head and neck cancer.

New Delhi, Nov 28 (PTI) Dr Reddy's Laboratories on Thursday said it has launched Toripalimab, a drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma in India. Nasopharyngeal ...

It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), ...

Dr. Reddy's entered into a licensing and commercialization agreement with Shanghai Junshi Biosciences for toripalimab.